Proteomics

Dataset Information

0

DYRK1A, a potential therapeutic target for head and neck squamous cell carcinoma

ABSTRACT: To identify the activated tyrosine kinase signaling pathways in HNSCC, we carried out phosphotyrosine profiling using a panel of HNSCC cell lines compared to a normal oral keratinocyte. A total of 61 unique phosphosites were identified across these cell lines. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) was one of the kinases hyperphosphorylated at Y321 in all the HNSCC cell lines compared to the normal oral cell line OKF6/TERT1. Inhibition of DYRK1A using its specific siRNA and inhibitor resulted in a decrease in the invasion and colony formation ability of the HNSCC cell lines. Further, the treatment of mice bearing HNSCC xenograft tumors with DYRK1A inhibitor (harmine) showed regression of tumor growth. Our results demonstrate that DYRK1A could be a novel therapeutic target in HNSCC.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Head And Neck Squamous Cell Carcinoma Cell Line

DISEASE(S): Head And Neck Squamous Cell Carcinoma

SUBMITTER: Akhilesh Pandey  

LAB HEAD: Akhilesh Pandey

PROVIDER: PXD002132 | Pride | 2018-10-24

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
HNSCC_TMT_pY1000_01.msf Msf
HNSCC_TMT_pY1000_01.pep.xml Pepxml
HNSCC_TMT_pY1000_01.prot.xml Xml
HNSCC_TMT_pY1000_01.raw Raw
Items per page:
1 - 4 of 4
altmetric image

Publications

Despite advances in clinical management, 5-year survival rate in patients with late-stage head and neck squamous cell carcinoma (HNSCC) has not improved significantly over the past decade. Targeted therapies have emerged as one of the most promising approaches to treat several malignancies. Though tyrosine phosphorylation accounts for a minority of total phosphorylation, it is critical for activation of signaling pathways and plays a significant role in driving cancers. To identify activated tyr  ...[more]

Similar Datasets

Proteomics Dysregulation of splicing proteins in head and neck squamous cell carcinoma
2018-10-24 | PXD001862 | Pride
Proteomics Identification of potential biomarkers of head and neck squamous cell carcinoma using iTRAQ based quantitative proteomic approach
2018-09-19 | PXD009241 | Pride
Proteomics Genetic aberrations in MAP kinase pathway play an important role in erlotinib resistance in head and neck cancer
2019-12-18 | PXD007785 | Pride
Proteomics SILAC-based quantitative tyrosine phosphoproteomic profiling identifies alternative therapeutic targets to erlotinib in head and neck squamous cell carcinoma
2022-10-13 | PXD007769 | Pride
Proteomics Phosphotyrosine profiling of curcumin-induced signaling
2018-10-24 | PXD002097 | Pride
Proteomics Molecular correlates of HNSCC engraftment
2024-04-09 | MSV000094507 | MassIVE
Transcriptomics Genome-wide gene expression analysis of EGFR inhibitor erlotinib-resistant and -sensitive head and neck squamous cell carcinoma cell lines Cal-27, SCC-25, FaDu, and SQ20B
2014-10-07 | GSE62061 | GEO
Proteomics Activating Mutations in PIK3CA result in Widespread Modulation of the Tyrosine Phosphoproteome
2018-10-24 | PXD001460 | Pride
Proteomics Chronic exposure to chewing tobacco induces growth in normal oral cells via overexpression of Stearoyl-CoA desaturase
2016-12-14 | PXD001554 | Pride
Proteomics Control of the mitochondrial carrier import pathway by DYRK1A
2021-05-31 | PXD019520 | Pride